Efficacy and safety of buprenorphine in patients receiving haemodialysis

Journal of Applied Therapeutic Research

Volumn 7, Issue 2, 2009, Pages 46-51

  Mordarski, Sylwester ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Buprenorphine; Chronic pain; Chronic renal failure; Haemodialysis; Tramadol

Indexed keywords

BUPRENORPHINE; TRAMADOL;

ADULT; AGED; ANALGESIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HEMODIALYSIS; HUMAN; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; SOMNOLENCE; VOMITING; WEAKNESS;

EID: 77958028073     PISSN: 10292659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bastani B and Jamal JA. Removal of morphine but not fentanyl during haemodialysis [letter]. Nephrology Dialysis Transplantation 1997;12:2802-2804.
2. Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliative Medicine 2006;20:17-23.
3. Chan GL and Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intelligence and Clinical Pharmacy 1987;21:773-783.
4. Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P and Duvaldestin P. Morphine pharmacokinetics in renal failure. Anesthesiology 1987;66:327-331.
5. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity and management. American Journal of Kidney Disease 2003;42:1239-1247.
6. Dean M. Opioids in renal failure and dialysis patients. Journal of Pain Symptom Management 2004;28:497-504.
7. Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J and Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. European Journal of Pain 2006;10:743-748.
8. Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. American Journal of Medicine 1996;101(suppl 1 A): S47-S53.
9. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ and Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. British Journal of Anaesthesiology 1990;64:276-282.
10. Heel RC, Brogden RN, Speight TM and Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-119.
11. Izzedine H, Launay-Vacher V, Abbara C, Aymard G, Bassilios N and Deray G. Pharmacokinetics of tramadol in a hemodialysis patient. [letter] Nephron 2002;92:755-756.
12. Kurella M, Bennett WM and Chertow GM. Analgesia in patients with ESRD: a review of available evidence. American Journal of Kidney Disease 2003;42:217-228.
13. Lewis KS and Han NH. Tramadol: A new centrally acting analgesic. American Journal of Health-System Pharmacy 1997;54:643-652.
14. Mordarski S, Lysenko L, Mróz B and Turkiewicz A. The analgesic ladder - an alternative option with regard to quality of life of oncologic patients. Polish Journal of Environmental Studies 2007;16:357-361.
15. Rance MJ and Shillingford JS. The role of the gut in the metabolism of strong analgesics. Biochemical Pharmacology 1976;25:735-741.
16. Sittl R, Likar R and Poulsen Nautrop B. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clinical Therapeutics 2005;27:225-237.
17. World Health Organization: Cancer pain relief. Geneva: WHO, (1996).